The severe cardiorenal syndrome: 'Guyton revisited'

Lennart G Bongartz1, Maarten Jan Cramer, Pieter A Doevendans

  • 1Department of Cardiology, Heart-Lung Centre Utrecht, Utrecht, The Netherlands.

European Heart Journal
|December 24, 2004
PubMed

Insights

The severe cardiorenal syndrome (SCRS) describes how combined heart and kidney failure worsens both conditions, leading to significantly higher cardiovascular risks. Understanding these interconnected cardiorenal pathways is crucial for improving patient outcomes.

Area of Science:

  • Cardiology
  • Nephrology
  • Pathophysiology

Background:

  • Increasing incidence of cardiac failure and chronic renal failure.
  • Co-existence of cardiac and renal failure presents a poor prognosis.
  • Existing hemodynamic models do not fully explain accelerated atherosclerosis and organ decline.

Purpose of the Study:

  • Propose the severe cardiorenal syndrome (SCRS) as a distinct pathophysiological entity.
  • Explore interactions between cardiorenal connectors in SCRS.
  • Elucidate the network of positive feedback loops in SCRS.

Main Methods:

  • Review of existing physiological frameworks (e.g., Guyton's model).
  • Analysis of key pathophysiological components: renin-angiotensin system, oxidative stress, inflammation, sympathetic nervous system.
  • Conceptual modeling of cardiorenal interactions.

Main Results:

  • Combined cardiac and renal dysfunction amplifies organ failure progression.
  • Cardiovascular morbidity and mortality are significantly elevated in SCRS patients.
  • Identified interactions between renin-angiotensin system, oxidative stress, inflammation, and sympathetic nervous system.

Conclusions:

  • SCRS is characterized by amplified progression of cardiac and renal failure.
  • Positive feedback loops among cardiorenal connectors form the basis of SCRS.
  • Further research into these interactions is warranted to improve management strategies.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
175
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
583
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
721
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
807
Renal Regulation of Acid-Base Balance01:29

Renal Regulation of Acid-Base Balance

Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
1.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
352